Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rVSV Nipah vaccine - Public Health Vaccines

Next Previous
Drug Profile

rVSV Nipah vaccine - Public Health Vaccines

Alternative Names: Nipah virus vaccine - Public Health Vaccines; PHV02; PHV02 Nipah vaccine - Public Health Vaccines; rVSV-Nipah vaccine - Public Health Vaccines; rVSV-ZEBOV-GP-NiV-G; rVSV∆G-EBOV GP/NiV G

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Nipah virus infections

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Nipah-virus-infections(Prevention) in USA (IM)
  • 01 Feb 2024 Public Health Vaccines initiates enrolment in a phase I trial for Nipah virus infections (Prevention) in USA (IM) (NCT06221813)
  • 30 May 2023 Public Health Vaccines LLC in collaboration with Coalition for Epidemic Preparedness Innovations completes a phase I trial in Nipah virus infections (Prevention) in USA (IM) (NCT05178901)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top